Axogen Inc vs Centene Corp — how do they compare? Axogen Inc trades at $48.35 (market cap $2.61B), while Centene Corp trades at $65.13 (market cap $32.05B). The key difference: Centene Corp is far larger — about 12.3× Axogen Inc's market cap. Which is the better fit depends on your goals.
| AXGN | CNC | |
|---|---|---|
Market Cap | $2.61B | $32.05B |
Sector | Technology | Health |
52-Week High | $48.48 | $68.72 |
52-Week Low | $14.16 | $26.17 |
Enterprise Value | $2.52B | $21.10B |
Signals from Pluang's Aura AI — not financial advice
AXGN is trading at $46.43, up 4.69% today, with strong technical momentum and bullish moving average signals. The company reported Q2 2026 revenue growth of 23.1% to $69.7 million and raised full-year guidance to at least $279 million. Despite recent earnings misses, analyst sentiment remains overwhelmingly positive with 84% buy ratings and a $54.33 price target.
The stock presents growth potential driven by expanding nerve care platform adoption and reimbursement improvements, but faces risks from persistent net losses (-$15.7M in 2025) and high valuation multiples (P/S 9.5). Near-term performance hinges on Q3 earnings delivery and continued commercial execution amid competitive pressures.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of September 2021, mostly in Medicaid (68% of membership), the individual exchanges (10%), Medicare Advantage (6%), and the balance in Tricare (West region), correctional facility, and international plans. The company also serves 4 million users through the Medicare Part D pharmaceutical program.
Read more on CNC →